The prevalence of heart failure (HF) is increasing throughout the world with high morbidity and mortality. Patients with advanced HF develop profound metabolic abnormalities including insulin resistance, cytokine activation and abnormal oxidative metabolism in the failing myocardium. Our previous work has shown accumulation of the toxic lipid intermediates ceramide and diacylglycerol in failing human myocardium and that these toxic lipids induce transcriptional changes, impaired cellular energy metabolism and inhibit insulin signaling. Further, preliminary animal studies revealed accumulation of long-chain ceramides in the failing myocardium. A pro-apoptotic state and enhanced proteolytic protein breakdown known to be associated with toxic lipid intermediates develops in advanced HF. Therefore, accumulation of toxic lipid intermediates such as long-chain ceramides might constitute a key link between altered cellular metabolism and proteolysis leading to impaired function and progressive cardiac remodeling in advanced HF. The central hypothesis of this application is that lipotoxic accumulation of long-chain ceramide species contributes to structural and functional myocardial changes in HF. We hypothesize that lipotoxicity is a key means of myocardial dysfunction but that distinct characteristics exist defined by the underlying cardiomyopathy. In myocardium from patients with ischemic and non-ischemic cardiomyopathies and non- diseased controls, we will analyze the myocardial lipid composition of ceramides, diacylglycerides, triglycerides, fatty acids, acylcarnitines, lipoxins and resolvins using LC/MS techniques. We also will study the impact of mechanical unloading through left ventricular assist device (LVAD) placement on myocardial metabolic derangements (AIM 1). Further, we will analyze pathways controlling gene and microRNA expression and link these to the results of the lipid composition analyses (AIM 2). Finally, we will analyze the cardiac lipid composition in animal models of human ischemic and non-ischemic cardiomyopathies and test whether pharmacologic and genetic inhibition of the de novo and salvage pathway of ceramide synthesis affects long-chain ceramide accumulation and progressive cardiac remodeling (AIM 3). In achieving the goals of this proposal, we will expand the understanding of key mechanisms underlying myocardial structural and functional derangements in HF. A major strength of this investigation is the ability to test the impact of long-chain ceramide accumulation on myocardial remodeling. Further, we will define the myocardial lipid pool in patients with advanced HF compared to controls and the impact of mechanical unloading of the failing myocardium. These studies will define new molecular and functional targets in patients with HF. The proposed work will, therefore, lay critical groundwork for broader clinical goals to define and enhance therapeutic strategies to modify molecular and transcriptional patterns of cardiac metabolism in HF.
This application addresses the mechanisms underlying central metabolic derangements in HF. We will define the myocardial ceramide pool in patients with advanced HF and its reversibility after mechanical unloading. Further, we study the impact of ceramide synthesis inhibition of myocardial infarct size and progression of heart failure. These studies will define new molecular pathways in HF and test novel therapeutic strategies to modify patterns of cardiac metabolism in HF.
|Brunjes, Danielle L; Dunlop, Mark; Wu, Christina et al. (2016) Analysis of Skeletal Muscle Torque Capacity and Circulating Ceramides in Patients with Advanced Heart Failure. J Card Fail 22:347-55|
|Kitada, Shuichi; Schulze, P Christian; Jin, Zhezhen et al. (2016) Comparison of early versus delayed timing of left ventricular assist device implantation as a bridge-to-transplantation: An analysis of the UNOS dataset. Int J Cardiol 203:929-35|
|Martin, Spencer T; Kato, Tomoko S; Farr, Maryjane et al. (2015) Similar survival in patients following heart transplantation receiving induction therapy using daclizumab vs. basiliximab. Circ J 79:368-74|
|Farr, Maryjane; Mitchell, James; Lippel, Matthew et al. (2015) Combination of liver biopsy with MELD-XI scores for post-transplant outcome prediction in patients with advanced heart failure and suspected liver dysfunction. J Heart Lung Transplant 34:873-82|
|Khawaja, Tuba; Greer, Christine; Thadani, Samir R et al. (2015) Increased regional epicardial fat volume associated with reversible myocardial ischemia in patients with suspected coronary artery disease. J Nucl Cardiol 22:325-33|
|Castillero, Estibaliz; Akashi, Hirokazu; Wang, Catherine et al. (2015) Cardiac myostatin upregulation occurs immediately after myocardial ischemia and is involved in skeletal muscle activation of atrophy. Biochem Biophys Res Commun 457:106-11|
|Derda, Anselm A; Thum, Sabrina; Lorenzen, Johan M et al. (2015) Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int J Cardiol 196:115-22|
|Kennel, Peter J; Mancini, Donna M; Schulze, P Christian (2015) Skeletal Muscle Changes in Chronic Cardiac Disease and Failure. Compr Physiol 5:1947-69|
|Zizola, Cynthia; Kennel, Peter J; Akashi, Hirokazu et al. (2015) Activation of PPARÎ´ signaling improves skeletal muscle oxidative metabolism and endurance function in an animal model of ischemic left ventricular dysfunction. Am J Physiol Heart Circ Physiol 308:H1078-85|
|Kennel, Peter J; Schulze, P Christian (2015) Novel Biomarker Approaches for Managing Patients With Cardiac Transplantation. Curr Heart Fail Rep 12:328-32|
Showing the most recent 10 out of 35 publications